

Oliver D Howes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3797796/oliver-d-howes-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

371
papers

21,321
citations

78
h-index

135
g-index

438
ext. papers

27,167
ext. citations

7
avg, IF

7.59
L-index

#	Paper	IF	Citations
371	White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis.. <i>Neuropsychopharmacology</i> , 2022 ,	8.7	1
370	Dopamine partial agonists and prodopaminergic drugs for schizophrenia: systematic review and meta-analysis of randomized controlled trials.. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 135, 104568	8.8	2
369	Striatal dopamine synthesis capacity and its association with negative symptoms upon resolution of positive symptoms in first-episode schizophrenia and delusional disorder.. <i>Psychopharmacology</i> , 2022 , 1	4.7	0
368	Assessing the impact of different penalty factors of the Bayesian reconstruction algorithm Q.Clear on in vivo low count kinetic analysis of [C]PHNO brain PET-MR studies.. <i>EJNMMI Research</i> , 2022 , 12, 11	3.6	0
367	Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis.. <i>NPJ Schizophrenia</i> , 2022 , 8, 19	5.5	
366	Low COVID-19 vaccination rates in people with severe mental illness and reasons for this: An out-patient study.. <i>Acta Psychiatrica Scandinavica</i> , 2022 , 145, 416-418	6.5	1
365	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.. <i>World Journal of Biological Psychiatry</i> , 2022 , 1-24	3.8	1
364	Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia.. <i>NPJ Schizophrenia</i> , 2022 , 8, 13	5.5	0
363	A cross-sectional MR study of body fat volumes and distribution in chronic schizophrenia.. <i>NPJ Schizophrenia</i> , 2022 , 8, 24	5.5	
362	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.. <i>Schizophrenia Research: Cognition</i> , 2022 , 29, 100249	2.8	3
361	The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.. <i>Psychopharmacology</i> , 2022 , 1	4.7	1
360	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study.. <i>British Journal of Psychiatry</i> , 2022 , 1-8	5.4	0
359	Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis.. <i>World Psychiatry</i> , 2022 , 21, 287-294	14.4	0
358	Individual and combined effects of cannabidiol and Δ^9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain. <i>Journal of Psychopharmacology</i> , 2022 , 36, 732-744	4.6	0
357	Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance.. <i>Biological Psychiatry</i> , 2022 ,	7.9	5
356	Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. <i>Molecular Psychiatry</i> , 2021 , 26, 2562-2576	15.1	18
355	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [C]Ro154513. <i>Molecular Psychiatry</i> , 2021 , 26, 2616-2625	15.1	17

354	Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. <i>BMJ Open</i> , 2021 , 11, e054160	3	0
353	New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 132, 324-361	9	5
352	Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function. <i>Translational Psychiatry</i> , 2021 , 11, 579	8.6	1
351	Translation From Genes to Mechanism in Schizophrenia: Are Immune-Synaptic Interactions the Missing Link?. <i>Biological Psychiatry</i> , 2021 , 90, 593-595	7.9	0
350	Need for care, adversity exposure and perceived stress in clinical and healthy voice-hearers. <i>Psychological Medicine</i> , 2021 , 51, 1944-1950	6.9	2
349	Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [F]DOPA and [C]raclopride PET study in first-episode psychosis. <i>Molecular Psychiatry</i> , 2021 , 26, 3476-3488	15.1	6
348	Striatal dopamine D receptors in medication-naïve schizophrenia: an [I] IBZM SPECT study. <i>Psychological Medicine</i> , 2021 , 1-9	6.9	1
347	Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis. <i>Neuropsychopharmacology</i> , 2021 , 46, 1484-1493	8.7	5
346	Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3530-3539	8.8	0
345	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. <i>Molecular Psychiatry</i> , 2021 ,	15.1	2
344	Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. <i>Neuropsychopharmacology</i> , 2021 , 46, 1468-1474	8.7	6
343	Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. <i>JAMA Psychiatry</i> , 2021 , 78, 490-497	14.5	8
342	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2021 , 11, 322	8.6	4
341	Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. <i>Behavioural Brain Research</i> , 2021 , 405, 113203	3.4	4
340	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. <i>JAMA Psychiatry</i> , 2021 , 78, 667-681	14.5	21
339	The Effects of Acute ΔTetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021 , 6, 660-667	3.4	
338	Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T. <i>Translational Psychiatry</i> , 2021 , 11, 367	8.6	4
337	Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness. <i>Science Advances</i> , 2021 , 7,	14.3	3

336	Adenosine A receptor in schizophrenia: an in vivo brain PET imaging study. <i>Psychopharmacology</i> , 2021 , 1	4.7	1
335	Brain volume in chronic ketamine users - relationship to sub-threshold psychotic symptoms and relevance to schizophrenia. <i>Psychopharmacology</i> , 2021 , 1	4.7	0
334	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. <i>Translational Psychiatry</i> , 2021 , 11, 393	8.6	6
333	The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. <i>Molecular Psychiatry</i> , 2021 , 26, 4464-4474	15.1	7
332	Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2021 , 47, 160-169	1.3	7
331	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biological Psychiatry</i> , 2021 , 89, e5-e8	7.9	16
330	The Cannabinoid CB Receptor in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021 , 6, 646-659	3.4	4
329	A potential biomarker for treatment stratification in psychosis: evaluation of an [F] FDOPA PET imaging approach. <i>Neuropsychopharmacology</i> , 2021 , 46, 1122-1132	8.7	10
328	Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis. <i>Human Brain Mapping</i> , 2021 , 42, 439-451	5.9	0
327	Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021 , 271, 677-687	5.1	3
326	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021 , 47, 505-516	1.3	14
325	The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. <i>Molecular Psychiatry</i> , 2021 , 26, 1310-1320	15.1	21
324	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal F-DOPA PET and voxel-based morphometry study. <i>Molecular Psychiatry</i> , 2021 , 26, 1332-1345	15.1	10
323	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021 , 47, 662-671	1.3	10
322	Parametric Mapping for TSPO PET Imaging with Spectral Analysis Impulsive Response Function. <i>Molecular Imaging and Biology</i> , 2021 , 23, 560-571	3.8	3
321	The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. <i>World Psychiatry</i> , 2021 , 20, 75-95	14.4	32
320	Positive symptom phenotypes appear progressively in "EDiPS", a new animal model of the schizophrenia prodrome. <i>Scientific Reports</i> , 2021 , 11, 4294	4.9	2
319	Treatment resistance in psychiatry: state of the art and new directions. <i>Molecular Psychiatry</i> , 2021 ,	15.1	9

318	Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis. <i>Lancet Psychiatry, the</i> , 2021 , 8, 589-598	23.3	6
317	The magnitude and variability of brain structural alterations in bipolar disorder: A double meta-analysis of 5534 patients and 6651 healthy controls. <i>Journal of Affective Disorders</i> , 2021 , 291, 171-176	6.6	4
316	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. <i>Translational Psychiatry</i> , 2021 , 11, 425	8.6	2
315	Psychophysiological stress-reactivity in clinical and non-clinical voice-hearers. <i>Schizophrenia Research</i> , 2021 , 235, 52-59	3.6	
314	Automated Data Quality Control in FDOPA brain PET Imaging using Deep Learning. <i>Computer Methods and Programs in Biomedicine</i> , 2021 , 208, 106239	6.9	4
313	Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	11
312	Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls. <i>World Psychiatry</i> , 2021 , 20, 405-416	14.4	5
311	Acute acetate administration increases endogenous opioid levels in the human brain: A [C]carfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , 2021 , 35, 606-610	4.6	1
310	Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
309	Adipose tissue dysfunction, inflammation, and insulin resistance: alternative pathways to cardiac remodelling in schizophrenia. A multimodal, case-control study. <i>Translational Psychiatry</i> , 2021 , 11, 614	8.6	1
308	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An PET Study With Neuropathological Comparison. <i>Frontiers in Neurology</i> , 2020 , 11, 541377	4.1	4
307	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020 , 45, 222-223	4.5	50
306	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , 2020 , 45, E1-E2	4.5	1
305	Stress resilience during the coronavirus pandemic. <i>European Neuropsychopharmacology</i> , 2020 , 35, 12-16	1.2	161
304	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , 2020 , 46, 1459-1470	1.3	16
303	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine) 2020 , 290-325		
302	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e204693	10.4	41
301	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. <i>Lancet Psychiatry, the</i> , 2020 , 7, 344-353	23.3	72

300	A neuroimaging biomarker for striatal dysfunction in schizophrenia. <i>Nature Medicine</i> , 2020 , 26, 558-565	50.5	45
299	The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders. <i>Neuropsychopharmacology</i> , 2020 , 45, 1878-1884	8.7	8
298	Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models. <i>Cerebral Cortex</i> , 2020 , 30, 3573-3589	5.1	10
297	Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 901-909	16.6	129
296	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. <i>Nature Communications</i> , 2020 , 11, 246	17.4	71
295	Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study. <i>British Journal of Psychiatry</i> , 2020 , 217, 450-457	5.4	7
294	Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020 , 88, 304-314	7.9	16
293	Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia. <i>Brain</i> , 2020 , 143, 1261-1277	11.2	19
292	Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome. <i>Schizophrenia Bulletin</i> , 2020 , 46, 670-679	1.3	12
291	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020 , 5, 1040-1051	3.4	5
290	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. <i>Focus (American Psychiatric Publishing)</i> , 2020 , 18, 456-465	1.1	4
289	M149. THE TOPOGRAPHY OF STRIATAL DOPAMINE AND SYMPTOMS IN PSYCHOSIS: AN INTEGRATIVE PET AND MRI STUDY. <i>Schizophrenia Bulletin</i> , 2020 , 46, S192-S192	1.3	78
288	Schizophrenia-An Overview. <i>JAMA Psychiatry</i> , 2020 , 77, 201-210	14.5	164
287	Treatment of First-Episode Schizophrenia in a Young Woman. <i>JAMA Psychiatry</i> , 2020 , 77, 211-212	14.5	0
286	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. <i>Molecular Psychiatry</i> , 2020 , 25, 1704-1717	15.1	15
285	Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. <i>World Psychiatry</i> , 2020 , 19, 15-33	14.4	124
284	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , 2020 , 6, 1	5.5	79
283	Serotonin release measured in the human brain: a PET study with [C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020 , 45, 804-810	8.7	17

282	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020 , 34, 3-78	4.6	85
281	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020 , 7, 64-77	23.3	229
280	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. <i>Neuropsychopharmacology</i> , 2020 , 45, 622-631	8.7	31
279	T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S238-S238	1.3	78
278	T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S248-S249	1.3	78
277	T79. BALANCING EFFECTS WITH SIDE-EFFECTS: EXAMINING COMPARATIVE METABOLIC CONSEQUENCES OF 18 ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA USING NETWORK META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S261-S262	1.3	78
276	M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S198-S198	1.3	78
275	S153. IMPAIRED THETA PHASE-COUPPLING BETWEEN HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S94-S94	1.3	78
274	S172. GLUTAMATE RELATED CONNECTIVITY DISTURBANCES OF THE SALIENCE AND DEFAULT MODE NETWORKS IN PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S102-S103	1.3	78
273	Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2020 , 119, 255-267	9	9
272	The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2020 , 34, 969-980	4.6	4
271	The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study. <i>Journal of Psychopharmacology</i> , 2020 , 34, 981-989	4.6	10
270	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S28-S28	1.3	78
269	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. <i>Journal of Affective Disorders</i> , 2020 , 276, 991-1000	6.6	7
268	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. <i>NPJ Schizophrenia</i> , 2020 , 6, 21	5.5	10
267	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 451-489	8.8	50
266	Understanding the genetics of neuropsychiatric disorders: the potential role of genomic regulatory blocks. <i>Molecular Psychiatry</i> , 2020 , 25, 6-18	15.1	16
265	Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. <i>Neuropsychopharmacology</i> , 2020 , 45, 641-648	8.7	16

264	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. <i>Neuropharmacology</i> , 2020 , 172, 107704	5.5	83
263	Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. <i>Biological Psychiatry</i> , 2020 , 87, 215-224	7.9	37
262	F107. THE EFFECTS OF DEVELOPMENTAL STRESS AND TRAUMA ON THE DOPAMINE SYSTEM. <i>Schizophrenia Bulletin</i> , 2019 , 45, S294-S294	1.3	78
261	O7.6. GABAA RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA: A PET STUDY USING [11C]-RO15. <i>Schizophrenia Bulletin</i> , 2019 , 45, S181-S182	1.3	78
260	Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. <i>Journal of Neural Transmission</i> , 2019 , 126, 1637-1651	4.3	37
259	Reduced mu opioid receptor availability in schizophrenia revealed with [C]-carfentanil positron emission tomographic Imaging. <i>Nature Communications</i> , 2019 , 10, 4493	17.4	19
258	Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. <i>Translational Psychiatry</i> , 2019 , 9, 163	8.6	18
257	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. <i>Psychopharmacology</i> , 2019 , 236, 3257-3270	4.7	13
256	The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging study. <i>Brain, Behavior, and Immunity</i> , 2019 , 80, 742-750	16.6	6
255	20.2 CANNABINOID 1 RECEPTOR AVAILABILITY AND MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET AND FUNCTIONAL MRI IMAGING STUDY. <i>Schizophrenia Bulletin</i> , 2019 , 45, S122-S122	1.3	78
254	32.4 A NOVEL TREATMENT FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA BY ENHANCING THE ACTIVITY OF PARVALBUMIN INTERNEURONS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S142-S143	1.3	2
253	41.2 THE EFFECTS OF DEVELOPMENTAL STRESS AND TRAUMA ON THE DOPAMINE SYSTEM. <i>Schizophrenia Bulletin</i> , 2019 , 45, S156-S156	1.3	78
252	F80. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS: PET AND MR IMAGING FINDINGS IN FIRST EPISODE AND CHRONIC SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2019 , 45, S284-S284	1.3	78
251	Understanding and Predicting Variability in Response to Treatment in Psychotic Disorders: In Vivo Findings. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1079-1081	6.1	22
250	Tobacco smoking and dopaminergic function in humans: a meta-analysis of molecular imaging studies. <i>Psychopharmacology</i> , 2019 , 236, 1119-1129	4.7	15
249	S84. THE EFFECT OF ANTIPSYCHOTICS ON GLUTAMATE LEVELS IN THE ANTERIOR CINGULATE AND CLINICAL RESPONSE MEASURED BY PANSS: A 1H-MRS STUDY IN FIRST-EPISODE PSYCHOSIS PATIENTS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S339-S339	1.3	78
248	O5.6. REMISSION FROM ANTIPSYCHOTIC TREATMENT IN FIRST EPISODE PSYCHOSIS RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S175-S175	1.3	78
247	O7.3. ALTERED HIPPOCAMPAL-STRIATAL-MIDBRAIN FUNCTION IN SUBJECTS AT CLINICAL HIGH RISK OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S180-S180	1.3	78

246	Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia. <i>NPJ Schizophrenia</i> , 2019 , 5, 6	5.5	8
245	Covariance statistics and network analysis of brain PET imaging studies. <i>Scientific Reports</i> , 2019 , 9, 2496	4.9	22
244	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2019 , 85, 79-87	7.9	36
243	Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. <i>Molecular Psychiatry</i> , 2019 , 24, 776-794	15.1	49
242	The effects of voice content on stress reactivity: A simulation paradigm of auditory verbal hallucinations. <i>Schizophrenia Research</i> , 2019 ,	3.6	1
241	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , 2019 , 5, 12	5.5	12
240	Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2019 , 10, 254	5	7
239	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. <i>Scientific Reports</i> , 2019 , 9, 8685	4.9	10
238	O2.1. CIRCUIT MECHANISM MEDIATES THE EFFECTS OF SUB-CHRONIC KETAMINE ON STRIATAL DOPAMINE SYNTHESIS CAPACITY AND LOCOMOTOR ACTIVITY: A COMBINED CHEMOGENETICS/PET STUDY. <i>Schizophrenia Bulletin</i> , 2019 , 45, S162-S162	1.3	78
237	Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study. <i>British Journal of Psychiatry</i> , 2019 , 215, 712-719	5.4	13
236	The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019 , 291, 34-41	2.9	8
235	Prevalence of treatment-resistant psychoses in the community: A naturalistic study. <i>Journal of Psychopharmacology</i> , 2019 , 33, 1248-1253	4.6	14
234	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2019 , 76, 1074-1084	14.5	32
233	Disrupted-in-schizophrenia 1 functional polymorphisms and D/D receptor availability: A [C]-(+)-PHNO imaging study. <i>Genes, Brain and Behavior</i> , 2019 , 18, e12596	3.6	
232	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. <i>European Neuropsychopharmacology</i> , 2019 , 29, 1333-1342	1.2	2
231	The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [C]-(+)-PHNO PET study. <i>Translational Psychiatry</i> , 2019 , 9, 287	8.6	10
230	O13.5. GLUTAMATERGIC METABOLITES ASSOCIATED WITH ALTERED HIPPOCAMPAL AND STRIATAL ACTIVATION DURING NOVELTY SALIENCE IN PEOPLE WITH A CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S202-S203	1.3	78
229	Task-induced functional brain connectivity mediates the relationship between striatal D2/3 receptors and working memory. <i>ELife</i> , 2019 , 8,	8.9	6

228	The effects of psychosocial stress on dopaminergic function and the acute stress response. <i>ELife</i> , 2019 , 8,	8.9	29
227	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. <i>Psychopharmacology</i> , 2019 , 236, 1985-1997	4.7	20
226	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	66
225	Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study. <i>Schizophrenia Research</i> , 2019 , 204, 381-388	3.6	9
224	Chronic psychosocial stressors are associated with alterations in salience processing and corticostriatal connectivity. <i>Schizophrenia Research</i> , 2019 , 213, 56-64	3.6	17
223	A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. <i>Schizophrenia Bulletin</i> , 2019 , 45, 1120-1133	1.3	61
222	Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2019 , 76, 199-207	14.5	41
221	Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [F]DOPA PET and fMRI study. <i>Psychological Medicine</i> , 2019 , 49, 2533-2542	6.9	7
220	A Unified Framework for Plasma Data Modeling in Dynamic Positron Emission Tomography Studies. <i>IEEE Transactions on Biomedical Engineering</i> , 2019 , 66, 1447-1455	5	12
219	Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. <i>Trends in Neurosciences</i> , 2019 , 42, 205-220	13.3	213
218	Neural Responsivity to Food Cues in Patients With Unmedicated First-Episode Psychosis. <i>JAMA Network Open</i> , 2019 , 2, e186893	10.4	8
217	Neuroinflammation in schizophrenia: meta-analysis of microglial imaging studies. <i>Psychological Medicine</i> , 2019 , 49, 2186-2196	6.9	85
216	Comment on " In Vivo [F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates". <i>ACS Chemical Neuroscience</i> , 2019 , 10, 768-772	5.7	10
215	Sex difference in brain CB1 receptor availability in man. <i>NeuroImage</i> , 2019 , 184, 834-842	7.9	37
214	Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study. <i>Biological Psychiatry</i> , 2019 , 85, 368-378	7.9	44
213	Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 874-885	7.3	28
212	Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. <i>Molecular Psychiatry</i> , 2019 , 24, 549-561	15.1	97
211	Determinants of treatment response in first-episode psychosis: an F-DOPA PET study. <i>Molecular Psychiatry</i> , 2019 , 24, 1502-1512	15.1	78

210	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. <i>Biological Psychiatry</i> , 2018 , 84, 433-442	7.9	80
209	Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 114-119	5.8	24
208	The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis. <i>Neuropsychopharmacology</i> , 2018 , 43, 1195-1196	8.7	3
207	The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [C]-raclopride PET study with aripiprazole. <i>Translational Psychiatry</i> , 2018 , 8, 87	8.6	14
206	Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project. <i>European Psychiatry</i> , 2018 , 50, 40-46	6	12
205	F18. IS SCHIZOPHRENIA A MULTI-SYSTEM DISORDER? CONSIDERING NEUROLOGICAL, IMMUNE, CARDIOMETABOLIC, AND ENDOCRINE ALTERATIONS IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018 , 44, S225-S226	1.3	78
204	The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 84, 152-159	5.5	12
203	Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis. <i>Neuropsychopharmacology</i> , 2018 , 43, 2652-2659	8.7	23
202	Amygdala reactivity in ethnic minorities and its relationship to the social environment: an fMRI study. <i>Psychological Medicine</i> , 2018 , 48, 1985-1992	6.9	8
201	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. <i>Schizophrenia Bulletin</i> , 2018 , 44, 1301-1311	1.3	96
200	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. <i>Brain</i> , 2018 , 141, 459-471	11.2	100
199	Kinetic modelling of [C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018 , 38, 1227-1242	7.3	45
198	Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 137, 39-46	6.5	48
197	The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. <i>Molecular Psychiatry</i> , 2018 , 23, 59-69	15.1	104
196	Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [C]PBR28 study. <i>Schizophrenia Research</i> , 2018 , 195, 206-214	3.6	35
195	The effects of haloperidol on microglial morphology and translocator protein levels: An in vivo study in rats using an automated cell evaluation pipeline. <i>Journal of Psychopharmacology</i> , 2018 , 32, 1264-1272	4.6	16
194	Phasic Stimulation of Midbrain Dopamine Neuron Activity Reduces Salt Consumption. <i>ENeuro</i> , 2018 , 5,	3.9	12
193	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2018 , 32, 3-29	4.6	116

192	Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [C]DASB PET study. <i>Human Psychopharmacology</i> , 2018 , 33, e2642 ²⁻³		6
191	Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT [C]CUMI-101 PET and Functional MRI Study. <i>Neuropsychopharmacology</i> , 2018 , 43, 655-664	8.7	34
190	O7.1. MIDBRAIN DOPAMINE NEURON ACTIVITY CONTROLS THE EFFECTS OF REPEATED KETAMINE ON STRIATAL DOPAMINERGIC FUNCTION. <i>Schizophrenia Bulletin</i> , 2018 , 44, S93-S93	1.3	78
189	S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION. <i>Schizophrenia Bulletin</i> , 2018 , 44, S395-S395	1.3	1
188	Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E10167-E10176 ¹¹⁻⁵	11.5	39
187	GABA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	26
186	Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort. <i>Schizophrenia Bulletin</i> , 2018 , 44, 1323-1331	1.3	38
185	The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. <i>Lancet Psychiatry</i> , 2018 , 5, 816-823	23.3	54
184	S19. EVIDENCE OF THE LIPID PARADOX IN PSYCHOSIS: A META-ANALYSIS OF CHOLESTEROL AND TRIGLYCERIDE LEVELS IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018 , 44, S330-S330	1.3	0
183	The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. <i>Human Molecular Genetics</i> , 2018 , 27, 3498-3506	5.6	5
182	The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. <i>Translational Psychiatry</i> , 2017 , 7, e1015	8.6	59
181	Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2017 , 74, 261-269	14.5	238
180	Regulation of dopaminergic function: an [F]-DOPA PET apomorphine challenge study in humans. <i>Translational Psychiatry</i> , 2017 , 7, e1027	8.6	45
179	Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. <i>Translational Psychiatry</i> , 2017 , 7, e1024	8.6	118
178	Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. <i>Psychological Medicine</i> , 2017 , 47, 1981-1989	6.9	121
177	The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 2017 , 174, 421-426	11.9	26
176	Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. <i>Psychological Medicine</i> , 2017 , 47, 243-254	6.9	25
175	Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [F]DOPA PET Study. <i>Neuropsychopharmacology</i> , 2017 , 42, 941-950	8.7	70

174	Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2017 , 74, 511-519	14.5	163
173	The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. <i>Molecular Psychiatry</i> , 2017 , 22, 666-679	15.1	224
172	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017 , 174, 216-229	11.9	408
171	Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017 , 211, 339-349	5.4	79
170	Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis. <i>JAMA Psychiatry</i> , 2017 , 74, 1104-1111	14.5	153
169	A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. <i>JAMA Psychiatry</i> , 2017 , 74, 1206-1213	14.5	124
168	30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis. <i>Schizophrenia Bulletin</i> , 2017 , 43, 1190-1196	1.3	127
167	Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis. <i>Translational Psychiatry</i> , 2017 , 7, e1245	8.6	32
166	Single cocaine exposure does not alter striatal pre-synaptic dopamine function in mice: an [¹⁸ F]-FDOPA PET study. <i>Journal of Neurochemistry</i> , 2017 , 143, 551-560	6	5
165	Hyperprolactinaemia in first episode psychosis - A longitudinal assessment. <i>Schizophrenia Research</i> , 2017 , 189, 117-125	3.6	21
164	Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. <i>Scientific Reports</i> , 2017 , 7, 15025	4.9	40
163	Auditory verbal hallucinations and continuum models of psychosis: A systematic review of the healthy voice-hearer literature. <i>Clinical Psychology Review</i> , 2017 , 51, 125-141	10.8	107
162	The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. <i>Biological Psychiatry</i> , 2017 , 81, 9-20	7.9	289
161	Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [¹¹ C]DASB PK-PD Study. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 371-381	6.2	6
160	Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese. <i>Trends in Psychiatry and Psychotherapy</i> , 2017 , 39, 110-115	2.3	5
159	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , 2017 , 43, 293-301	1.3	38
158	The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. <i>ELife</i> , 2017 , 6,	8.9	21
157	Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study. <i>American Journal of Psychiatry</i> , 2016 , 173, 44-52	11.9	286

156	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. <i>Psychological Medicine</i> , 2016 , 46, 3231-3240	6.9	141
155	The effects of Δ-tetrahydrocannabinol on the dopamine system. <i>Nature</i> , 2016 , 539, 369-377	50.4	176
154	Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. <i>British Journal of Psychiatry</i> , 2016 , 209, 361-365	5.4	152
153	Response to Narendran and Frankle: The Interpretation of PET Microglial Imaging in Schizophrenia. <i>American Journal of Psychiatry</i> , 2016 , 173, 537-8	11.9	8
152	Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis. <i>American Journal of Psychiatry</i> , 2016 , 173, 392-9	11.9	68
151	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2016 , 30, 495-553 ^{4.6}	4.6	468
150	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. <i>American Journal of Psychiatry</i> , 2016 , 173, 714-21	11.9	26
149	Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. <i>Psychopharmacology</i> , 2016 , 233, 1637-50	4.7	288
148	Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis. <i>Psychiatry Research</i> , 2016 , 238, 270-276	9.9	9
147	Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. <i>Psychopharmacology</i> , 2016 , 233, 1605-21	4.7	47
146	Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. <i>Lancet Psychiatry</i> , 2016 , 3, 451-63	23.3	74
145	An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications. <i>Comprehensive Psychiatry</i> , 2016 , 66, 39-45	7.3	8
144	Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. <i>Schizophrenia Bulletin</i> , 2016 , 42, 744-52	1.3	120
143	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. <i>Biological Psychiatry</i> , 2016 , 80, e19-e20	7.9	1
142	Adversity in childhood linked to elevated striatal dopamine function in adulthood. <i>Schizophrenia Research</i> , 2016 , 176, 171-176	3.6	58
141	Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. <i>Psychological Medicine</i> , 2016 , 46, 357-66	6.9	17
140	Consistent biological findings in major depression: Results from serotonin transporter meta-analyses. <i>Journal of Affective Disorders</i> , 2016 , 199, 171	6.6	
139	HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis. <i>Translational Psychiatry</i> , 2016 , 6, e797	8.6	18

138	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. <i>American Journal of Human Genetics</i> , 2016 , 98, 735-43	11	48
137	Schizophrenia: inorganic no more. <i>Lancet Psychiatry</i> , 2016 , 3, 600-2	23.3	5
136	Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. <i>British Journal of Psychiatry</i> , 2015 , 207, 130-134	5.4	54
135	The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. <i>Journal of Affective Disorders</i> , 2015 , 186, 358-66	6.6	52
134	Magnetic Resonance and Molecular Imaging in Psychiatry 2015 , 439-445		
133	Further human evidence for striatal dopamine release induced by administration of Δ^9 -tetrahydrocannabinol (THC): selectivity to limbic striatum. <i>Psychopharmacology</i> , 2015 , 232, 2723-9	4.7	85
132	Presynaptic Serotonergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study. <i>Biological Psychiatry</i> , 2015 , 78, 563-571	7.9	16
131	Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation. <i>Schizophrenia Bulletin</i> , 2015 , 41, 429-39	1.3	51
130	The methodology of TSPO imaging with positron emission tomography. <i>Biochemical Society Transactions</i> , 2015 , 43, 586-92	5.1	163
129	Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?. <i>NPJ Schizophrenia</i> , 2015 , 1, 15036	5.5	
128	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. <i>Journal of Psychopharmacology</i> , 2015 , 29, 892-7	4.6	38
127	Interpreting the neurodevelopmental hypothesis of schizophrenia in the context of normal brain development and ageing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E2745	11.5	8
126	Very Early Brain Damage Leads to Remodeling of the Working Memory System in Adulthood: A Combined fMRI/Tractography Study. <i>Journal of Neuroscience</i> , 2015 , 35, 15787-99	6.6	30
125	Sensory gating deficits in the attenuated psychosis syndrome. <i>Schizophrenia Research</i> , 2015 , 161, 277-82	3.6	9
124	Commentary on a study of the prevalence of mental disorders by Breslau et al. <i>Journal of Psychiatric Research</i> , 2015 , 61, 231-2	5.2	1
123	Prevalence of serum N-methyl-D-aspartate receptor autoantibodies in refractory psychosis. <i>British Journal of Psychiatry</i> , 2015 , 206, 164-5	5.4	21
122	Glutamate and dopamine in schizophrenia: an update for the 21st century. <i>Journal of Psychopharmacology</i> , 2015 , 29, 97-115	4.6	428
121	The role of white matter abnormalities in treatment-resistant depression: a systematic review. <i>Current Pharmaceutical Design</i> , 2015 , 21, 1337-46	3.3	12

120	Dopaminergic basis of salience dysregulation in psychosis. <i>Trends in Neurosciences</i> , 2014 , 37, 85-94	13.3	162
119	Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. <i>Psychopharmacology</i> , 2014 , 231, 2107-16	4.7	27
118	Schizophrenia: an integrated sociodevelopmental-cognitive model. <i>Lancet, The</i> , 2014 , 383, 1677-1687	40	470
117	Neuropathological changes in the substantia nigra in schizophrenia but not depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014 , 264, 285-96	5.1	29
116	Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2014 , 45, 233-45	9	129
115	Dopamine function in cigarette smokers: an [¹⁸ F]-DOPA PET study. <i>Neuropsychopharmacology</i> , 2014 , 39, 2397-404	8.7	37
114	Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [¹¹ C]MePPEP. <i>NeuroImage</i> , 2014 , 97, 151-62	7.9	15
113	Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. <i>Biological Psychiatry</i> , 2014 , 75, e11-3	7.9	218
112	Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. <i>Neuropsychopharmacology</i> , 2014 , 39, 2891-9	8.7	69
111	Cognitive therapy: at last an alternative to antipsychotics?. <i>Lancet, The</i> , 2014 , 383, 1364-6	40	10
110	Does human presynaptic striatal dopamine function predict social conformity?. <i>Journal of Psychopharmacology</i> , 2014 , 28, 237-43	4.6	4
109	The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014 , 34, 827-35	7.3	31
108	Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. <i>British Journal of Psychiatry</i> , 2014 , 204, 420-9	5.4	86
107	The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 130, 427-38	6.5	25
106	Practitioner attitudes to clozapine initiation. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 130, 16-24	6.5	82
105	Cannabis use and transition to psychosis in people at ultra-high risk. <i>Psychological Medicine</i> , 2014 , 44, 2503-12	6.9	60
104	Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation. <i>Frontiers in Psychiatry</i> , 2014 , 5, 149	5	45
103	Spatial working memory ability in individuals at ultra high risk for psychosis. <i>Journal of Psychiatric Research</i> , 2014 , 50, 100-105	5.2	26

102	Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. <i>Biological Psychiatry</i> , 2014 , 75, 470-8	7.9	143
101	The relationship between reward and punishment processing and the 5-HT1A receptor as shown by PET. <i>Psychopharmacology</i> , 2014 , 231, 2579-86	4.7	7
100	The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. <i>Psychopharmacology</i> , 2014 , 231, 2251-9	4.7	72
99	Dopamine and the Biology and Course of Treatment Resistance 2014 , 31-43		
98	The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole. <i>Psychopharmacology</i> , 2013 , 227, 221-9	4.7	38
97	Optimising treatment of refractory schizophrenia. <i>Psychopharmacology</i> , 2013 , 227, 373-4	4.7	3
96	Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use. <i>Psychopharmacology</i> , 2013 , 225, 41-50	4.7	11
95	Vitamin D deficiency in first episode psychosis: a case-control study. <i>Schizophrenia Research</i> , 2013 , 150, 533-7	3.6	65
94	Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. <i>Brain</i> , 2013 , 136, 3242-51	11.2	103
93	Mind the mortality gap: the importance of metabolic function in mental illnesses. <i>Psychopharmacology</i> , 2013 , 230, 1-2	4.7	1
92	Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. <i>Biological Psychiatry</i> , 2013 , 74, 106-12	7.9	161
91	AuthorsPreply. <i>British Journal of Psychiatry</i> , 2013 , 202, 155	5.4	
90	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. <i>Neuropharmacology</i> , 2013 , 68, 195-201	5.5	79
89	Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study. <i>Neuropsychopharmacology</i> , 2013 , 38, 485-91	8.7	29
88	Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 914-20	7.3	17
87	Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. <i>Schizophrenia Bulletin</i> , 2013 , 39, 1328-36	1.3	145
86	Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis. <i>Schizophrenia Bulletin</i> , 2013 , 39, 378-86	1.3	36
85	Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations. <i>Schizophrenia Bulletin</i> , 2013 , 39, 807-14	1.3	65

84	AuthorsPreply. <i>British Journal of Psychiatry</i> , 2013 , 202, 238	5.4	
83	Facial and prosodic emotion recognition deficits associate with specific clusters of psychotic symptoms in schizophrenia. <i>PLoS ONE</i> , 2013 , 8, e66571	3.7	31
82	Molecular imaging as a guide for the treatment of central nervous system disorders. <i>Dialogues in Clinical Neuroscience</i> , 2013 , 15, 315-28	5.7	13
81	Limbic striatal dopamine D2/3 receptor availability is associated with non-planning impulsivity in healthy adults after exclusion of potential dissimulators. <i>Psychiatry Research - Neuroimaging</i> , 2012 , 202, 60-4	2.9	33
80	Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. <i>Human Psychopharmacology</i> , 2012 , 27, 15-23	2.3	39
79	Antipsychotic drugs for prevention of relapse. <i>Lancet, The</i> , 2012 , 379, 2030-1	4.0	2
78	Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 759-68	7.3	24
77	Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. <i>American Journal of Psychiatry</i> , 2012 , 169, 1203-10	11.9	230
76	Delusional ideation, manic symptomatology and working memory in a cohort at clinical high-risk for psychosis: a longitudinal study. <i>European Psychiatry</i> , 2012 , 27, 258-63	6	17
75	The nature of dopamine dysfunction in schizophrenia and what this means for treatment. <i>Archives of General Psychiatry</i> , 2012 , 69, 776-86		616
74	Reduced mismatch negativity predates the onset of psychosis. <i>Schizophrenia Research</i> , 2012 , 134, 42-8	3.6	95
73	Functional brain networks before the onset of psychosis: A prospective fMRI study with graph theoretical analysis. <i>NeuroImage: Clinical</i> , 2012 , 1, 91-8	5.3	28
72	Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. <i>Molecular Psychiatry</i> , 2012 , 17, 1254-60	15.1	56
71	Molecular Imaging in Schizophrenia. <i>NeuroMethods</i> , 2012 , 305-321	0.4	
70	Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies. <i>Journal of Psychiatry and Neuroscience</i> , 2012 , 37, 170-84	4.5	94
69	Quantification of ligand PET studies using a reference region with a displaceable fraction: application to occupancy studies with [(11)C]-DASB as an example. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 70-80	7.3	28
68	Cognitive functioning in prodromal psychosis: a meta-analysis. <i>Archives of General Psychiatry</i> , 2012 , 69, 562-71		454
67	Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1268-76	1.3	95

66	History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. <i>Journal of Psychopharmacology</i> , 2012 , 26, 144-9	4.6	49
65	Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1040-9	1.3	56
64	Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. <i>British Journal of Psychiatry</i> , 2012 , 201, 481-5	5.4	220
63	Interpersonal sensitivity in the at-risk mental state for psychosis. <i>Psychological Medicine</i> , 2012 , 42, 1835-45	4.5	50
62	Sexual dysfunction in people with prodromal or first-episode psychosis. <i>British Journal of Psychiatry</i> , 2012 , 201, 131-6	5.4	34
61	Economic impact of early detection and early intervention of psychosis. <i>Current Pharmaceutical Design</i> , 2012 , 18, 592-5	3.3	19
60	From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. <i>Current Pharmaceutical Design</i> , 2012 , 18, 459-65	3.3	43
59	Reply to: Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis. <i>Biological Psychiatry</i> , 2011 , 70, e3-e4	7.9	
58	Striatal dopamine synthesis capacity in twins discordant for schizophrenia. <i>Psychological Medicine</i> , 2011 , 41, 2331-8	6.9	48
57	Characterization of the anterior cingulate's role in the at-risk mental state using graph theory. <i>NeuroImage</i> , 2011 , 56, 1531-9	7.9	44
56	Is clinical intervention in the ultra high risk phase effective?. <i>Revista Brasileira De Psiquiatria</i> , 2011 , 33 Suppl 2, s161-74	2.6	3
55	An overview of functional, structural and neurochemical imaging studies in individuals with a clinical high risk for psychosis. <i>Neuropsychiatry</i> , 2011 , 1, 477-493	1.8	7
54	Calculating occupancy when one does not have baseline: a comparison of different options. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011 , 31, 1760-7	7.3	7
53	Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. <i>Molecular Psychiatry</i> , 2011 , 16, 67-75	15.1	175
52	Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. <i>Molecular Psychiatry</i> , 2011 , 16, 885-6	15.1	195
51	The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹ C]raclopride PET study. <i>Psychopharmacology</i> , 2011 , 217, 515-23	4.7	11
50	Early detection and intervention in bipolar affective disorder: targeting the development of the disorder. <i>Current Psychiatry Reports</i> , 2011 , 13, 493-9	9.1	27
49	Dopamine synthesis capacity before onset of psychosis: a prospective [¹⁸ F]-DOPA PET imaging study. <i>American Journal of Psychiatry</i> , 2011 , 168, 1311-7	11.9	256

48	A comprehensive review and model of putative prodromal features of bipolar affective disorder. <i>Psychological Medicine</i> , 2011 , 41, 1567-77	6.9	83
47	Presynaptic 5-HT1A is related to 5-HTT receptor density in the human brain. <i>Neuropsychopharmacology</i> , 2011 , 36, 2258-65	8.7	34
46	Mind the translation gap: problems in the implementation of early intervention services. <i>Psychological Medicine</i> , 2010 , 40, 171-2	6.9	3
45	Impaired verbal self-monitoring in individuals at high risk of psychosis. <i>Psychological Medicine</i> , 2010 , 40, 1433-42	6.9	28
44	Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. <i>Archives of General Psychiatry</i> , 2010 , 67, 683-91		205
43	Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. <i>Biological Psychiatry</i> , 2010 , 68, 599-602	7.9	107
42	Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. <i>NeuroImage</i> , 2010 , 50, 260-6	7.9	24
41	The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. <i>NeuroImage</i> , 2010 , 50, 524-531	7.9	106
40	Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding. <i>Synapse</i> , 2010 , 64, 301-12	2.4	18
39	Integrating the Epidemiology and Pathogenesis of Schizophrenia from the Street to the Striatum: Integrating the Epidemiology and Pathogenesis of Schizophrenia 2010 , 357-366		
38	Elevated striatal dopamine function linked to prodromal signs of schizophrenia. <i>Archives of General Psychiatry</i> , 2009 , 66, 13-20		557
37	Julius Wagner-Jauregg, 1857-1940. <i>American Journal of Psychiatry</i> , 2009 , 166, 409	11.9	4
36	The dopaminergic basis of human behaviors: A review of molecular imaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2009 , 33, 1109-32	9	126
35	The dopamine hypothesis of schizophrenia: version III--the final common pathway. <i>Schizophrenia Bulletin</i> , 2009 , 35, 549-62	1.3	1721
34	Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. <i>Biological Psychiatry</i> , 2009 , 65, 473-80	7.9	56
33	Functionally defined regions may aid interpretation of striatal dopamine elevation in schizophrenia. <i>Schizophrenia Research</i> , 2009 , 109, 200	3.6	1
32	The effect of ageing on grey and white matter reductions in schizophrenia. <i>Schizophrenia Research</i> , 2009 , 112, 7-13	3.6	35
31	Sex hormone augmentation as an adjunctive treatment in schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 195-6; author reply 196-7	1.7	1

30	Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. <i>Current Pharmaceutical Design</i> , 2009 , 15, 2550-9	3.3	181
29	Multimodal functional imaging investigation before and after the onset of psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 579-81	5.8	4
28	Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. <i>Schizophrenia Research</i> , 2008 , 106, 148-55	3.6	56
27	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. <i>Trends in Pharmacological Sciences</i> , 2008 , 29, 91-8	13.2	120
26	Abnormal P300 in people with high risk of developing psychosis. <i>NeuroImage</i> , 2008 , 41, 553-60	7.9	76
25	Longitudinal PET imaging in a patient with schizophrenia did not show marked changes in dopaminergic function with relapse of psychosis. <i>American Journal of Psychiatry</i> , 2008 , 165, 1613-4	11.9	6
24	Understanding pathophysiology is crucial in linking clinical staging to targeted therapeutics. <i>World Psychiatry</i> , 2008 , 7, 162-3	14.4	1
23	Brain signs and vulnerability to psychosis. <i>British Journal of Psychiatry</i> , 2008 , 193, 168	5.4	15
22	Street slang and schizophrenia. <i>BMJ, The</i> , 2007 , 335, 1294	5.9	1
21	Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 361-7	4.6	64
20	The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 629-31	1.7	8
19	Serum glutamic acid decarboxylase 65 antibody levels in people with schizophrenia and their families. <i>Schizophrenia Research</i> , 2005 , 73, 379-81	3.6	3
18	Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 259-61	1.7	51
17	Comments on "Prolactin levels and erectile function in patients treated with risperidone" (J Clin Psychopharmacol 2004;24:161-166). <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 393-4	1.7	1
16	Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. <i>British Journal of Psychiatry</i> , 2004 , 184, 503-8	5.4	159
15	Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1649	2.5	3
14	Alendronic acid for antipsychotic-related osteopenia. <i>American Journal of Psychiatry</i> , 2004 , 161, 756	11.9	7
13	Pathways to schizophrenia: the impact of environmental factors. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7 Suppl 1, S7-S13	5.8	128

12	Bone mineral density and prolactin associations in patients with chronic schizophrenia. <i>Schizophrenia Research</i> , 2004 , 66, 77-8	3.6	3
11	A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. <i>American Journal of Psychiatry</i> , 2004 , 161, 361-3	11.9	59
10	The effect of clozapine on factors controlling glucose homeostasis. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 1352-5	4.6	12
9	Hyperprolactinaemia caused by antipsychotic drugs 2002 , 324, 1278-1278		6
8	Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. <i>BMJ, The</i> , 2002 , 324, 1278	5.9	3
7	Manic psychosis induced by long term alpha-interferon treatment for hepatitis C. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000 , 4, 161-162	2.4	4
6	Environmentally friendly health care begins in Madagascar. <i>Lancet, The</i> , 1998 , 351, 577	4.0	11
5	Health anxiety in medical students. <i>Lancet, The</i> , 1998 , 351, 1332	4.0	14
4	Variability of glucose, insulin, and lipid disturbances in first-episode psychosis: a meta-analysis. <i>Psychological Medicine</i> , 1-7	6.9	0
3	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis		1
2	The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study		1
1	Body fat volumes and distribution in chronic schizophrenia compared to healthy controls; a cross-sectional MR study		1